company background image
530019 logo

Jubilant Pharmova BSE:530019 Stock Report

Last Price

₹1.13k

Market Cap

₹178.3b

7D

-1.5%

1Y

49.3%

Updated

16 Jun, 2025

Data

Company Financials +

Jubilant Pharmova Limited

BSE:530019 Stock Report

Market Cap: ₹178.3b

530019 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Jubilant Pharmova Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Jubilant Pharmova
Historical stock prices
Current Share Price₹1,125.95
52 Week High₹1,309.00
52 Week Low₹701.40
Beta0.80
1 Month Change19.09%
3 Month Change26.49%
1 Year Change49.25%
3 Year Change249.95%
5 Year Change73.62%
Change since IPO4,939.22%

Recent News & Updates

Recent updates

Shareholder Returns

530019IN PharmaceuticalsIN Market
7D-1.5%1.1%-1.0%
1Y49.3%13.1%0.4%

Return vs Industry: 530019 exceeded the Indian Pharmaceuticals industry which returned 13% over the past year.

Return vs Market: 530019 exceeded the Indian Market which returned -0.3% over the past year.

Price Volatility

Is 530019's price volatile compared to industry and market?
530019 volatility
530019 Average Weekly Movement6.4%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement6.5%
10% most volatile stocks in IN Market9.3%
10% least volatile stocks in IN Market4.4%

Stable Share Price: 530019 has not had significant price volatility in the past 3 months compared to the Indian market.

Volatility Over Time: 530019's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19785,399Priyavrat Bhartiawww.jubilantpharmova.com

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others.

Jubilant Pharmova Limited Fundamentals Summary

How do Jubilant Pharmova's earnings and revenue compare to its market cap?
530019 fundamental statistics
Market cap₹178.30b
Earnings (TTM)₹8.39b
Revenue (TTM)₹72.35b
21.2x
P/E Ratio
2.5x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
530019 income statement (TTM)
Revenue₹72.35b
Cost of Revenue₹23.17b
Gross Profit₹49.18b
Other Expenses₹40.78b
Earnings₹8.39b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)53.01
Gross Margin67.97%
Net Profit Margin11.60%
Debt/Equity Ratio39.1%

How did 530019 perform over the long term?

See historical performance and comparison

Dividends

0.4%
Current Dividend Yield
9%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/16 23:27
End of Day Share Price 2025/06/16 00:00
Earnings2025/03/31
Annual Earnings2025/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Jubilant Pharmova Limited is covered by 31 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Harith AhamedAvendus Spark
Deepak KhetanAxis Capital Limited
Gaurav ChughBatlivala & Karani Securities India Pvt. Ltd.